HAMBURG, Germany and OXFORD, England, February 9 /PRNewswire-FirstCall/ -- Evotec AG today announced that the Company will give a corporate presentation and participate in a focus panel session at the upcoming BIO CEO & Investor Conference, which will take place on 14 to 15 February 2006 at the Waldorf=Astoria Hotel in New York.
Evotec is one of the four companies selected to participate in the panel discussion, CNS Disorders: Alzheimer's and Parkinson's - What is on the Horizon?, which will take place at 08.30 a.m. (EST) on Wednesday, 15 February 2006 in the East Foyer of the hotel. The panel will focus on novel approaches to the treatment of these CNS diseases and the corresponding market potential for these advances. Evotec has two class leading Alzheimer disease compounds in clinical development: EVT 301, a selective and reversible inhibitor of MAO-B with potential to slow disease progression, and EVT 101, a subtype selective NMDA receptor antagonist for symptomatic treatment. Dr John Kemp, Executive VP R&D Pharmaceuticals Division of Evotec, will represent the Company at this panel.
The Company presentation will take place on Wednesday, 15 February 2006 at 03.30 p.m. (EST) in the Basildon Room of the hotel. It will be webcast live and will be accessible through the Evotec website at www.evotec.com - Investors. A replay will also be available via the website.
Contact: Evotec AG Anne Hennecke Director, Investor Relations & Corporate Communications Phone: +49-40-56081-286 Fax: +49-40-56081-333 E-Mail: anne.hennecke@evotec.com
Evotec AGCONTACT: Contact: Evotec AG, Anne Hennecke, Director, Investor Relations &Corporate Communications, Phone: +49-40-56081-286, Fax: +49-40-56081-333,E-Mail: anne.hennecke@evotec.com
